Both models warn that the MATCH Act presents a structural headwind by targeting DUV sales to China, which accounts for approximately 33% of 2025 revenue and a projected 10% EPS hit. They agree the stock is currently overbought, trading above the upper Bollinger Band ($1,437.75) and nearing key resistance at $1,453.54, suggesting the recent rally is technically exhausted. This creates a poor risk/reward profile where the April 15 earnings and upcoming PCE data could trigger a sharp reversal if guidance reflects the full impact of export controls.
All 3 models highlight ASML's strong technical momentum, noting the stock has reclaimed key moving averages (4H SMA20/50) and is testing $1,453 resistance within a confirmed bullish macro regime. Two models emphasize that the market has already absorbed the initial MATCH Act shock, with idiosyncratic strength and ongoing buybacks providing a structural bid ahead of the April 15 earnings report. If buyers convert current resistance into support, the thin-volume zone could accelerate price toward a $1,540–$1,556 target, supported by a history of significant EPS beats.
ASML faces a structural revenue headwind from the proposed MATCH Act, which would ban DUV lithography sales and servicing to China — a market representing ~33% of 2025 revenues. JPM organ estimates up to a 10% EPS hit, and the stock is already trading above its 4H Bollinger upper band ( $1, 437.75) and within 0.4% of key resistance at $1, 453.54, suggesting the recent bounce is technically exhausted. With Q1 2026 earnings on April 15 and a high-impact PCE macro event within 24 hours, the risk/reward favors fading this rally into resistance before the market fully prices in the export control damage.
ASML has recovered sharply from its April 7 MATCH Act sell-off, reclaiming both the 4H SMA20 ( $1, 334) and SMA50 ( $1, 351) and trading above the upper Bollinger Band — a sign of genuine momentum, not just a dead-cat bounce. The macro regime is confirmed trending/bullish, the broader equity tape is supportive, and ASML's ongoing share buyback program provides a structural bid. With Q1 2026 earnings due April 15 and the last three quarters all delivering positive EPS surprises (most recently +16.1%) , a catalyst-driven re-rating toward the $1, 540 resistance zone is plausible within the near-term horizon.
Thesis Competition: BEAR case won (49% vs 45%).
ASML still has a credible near-term long despite the MATCH Act overhang because the stock has already absorbed the initial export-control shock, recovered sharply, and is pressing $1453 resistance with rising 4h and daily momentum while trading above all key moving averages in a confirmed bullish equity regime. If buyers convert this area into support, the thin-volume zone from roughly $1481 to $1508 can accelerate price toward the prior high and our $1556 target, helped by ongoing buybacks and anticipation into the Apr. 15 earnings report after January’s 16.1% EPS beat. This explicitly contradicts the research desk’s bearish timing call: the structural China risk is real, but the near-term tape is showing bad-news absorption and idiosyncratic relative strength versus QQQ and XLK.
ASML has rebounded straight back into the $1453 resistance area with 30-minute RSI at 74.38, price above the 4-hour upper Bollinger Band, and the stock stretched 8.5% above its 4-hour SMA20, which is a classic mean-reversion setup rather than fresh low-risk entry. The rally is also happening on falling 5-day volume and without confirmation from nearby beta proxies like QQQ and XLK, making today’s strength look more idiosyncratic and fragile than broadly sponsored. With the MATCH Act export-control overhang still threatening China-linked DUV revenue, a rich 49.9x P/E, PCE event risk inside 24 hours, and Q1 results due April 15, a failed breakout here can unwind quickly back toward the low-$1300s over the next several sessions.
Thesis Competition: BULL case won (55% vs 54%).
ASML faces a structural headwind from the proposed MATCH Act, which targets its DUV lithography tool sales to China (33% of 2025 revenue) . With JPM organ estimating a 10% EPS reduction and the stock trading near resistance ( $1453.54) in an overbought state (RSI 65.19, above Bollinger upper band) , the risk-reward favors a short. The upcoming earnings report (April 15) could amplify downside if guidance reflects these restrictions.
ASML is positioned for a trend continuation in a bullish macro regime, with strong technical momentum (RSI rising, MACD expanding, price above key SMAs) and supportive cross-asset signals. The upcoming Q1 earnings report on April 15, 2026, could act as a catalyst, especially if guidance mitigates concerns over the MATCH Act's impact. The stock is trading just below resistance at $1453.54, and a breakout could drive further upside.
Thesis Competition: BEAR case won (47% vs 41%).